目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary interviews
2.2.1.4 Approach 4: Growth Forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 STUDY-RELATED ASSUMPTIONS
2.4.2 GROWTH RATE ASSUMPTIONS
2.5 RISK ASSESSMENT
2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 LATERAL FLOW ASSAYS MARKET OVERVIEW
4.2 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY APPLICATION AND COUNTRY
4.3 LATERAL FLOW ASSAYS MARKET, BY COUNTRY
4.4 LATERAL FLOW ASSAYS MARKET: REGIONAL MIX
4.5 LATERAL FLOW ASSAYS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 High prevalence of infectious diseases
5.2.1.2 Rise in geriatric population
5.2.1.3 Growing use of home-based lateral flow assay devices
5.2.1.4 Growth in demand for POC testing
5.2.2 RESTRAINTS
5.2.2.1 Inconsistent results of lateral flow assays
5.2.3 OPPORTUNITIES
5.2.3.1 Evolving applications of lateral flow assays
5.2.3.2 Rise in demand for lateral flow assays in food & beverage industry
5.2.4 CHALLENGES
5.2.4.1 Limited reimbursements for lateral flow assay products
5.2.4.2 Difficulties in procuring quality raw materials to develop tests
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 Immunochromatography
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Lyophilization (Freeze-drying) Technologies
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAYS)
5.4 PORTER'S FIVE FORCES ANALYSIS
5.4.1 BARGAINING POWER OF SUPPLIERS
5.4.2 BARGAINING POWER OF BUYERS
5.4.3 THREAT OF NEW ENTRANTS
5.4.4 THREAT OF SUBSTITUTES
5.4.5 INTENSITY OF COMPETITIVE RIVALRY
5.5 REGULATORY LANDSCAPE
5.5.1 REGULATORY ANALYSIS
5.5.1.1 North America
5.5.1.2 Europe
5.5.1.3 Asia Pacific
5.5.1.3.1 India
5.5.1.3.2 China
5.5.1.3.3 Japan
5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5.2.1 North America
5.5.2.2 Europe
5.5.2.3 Asia Pacific
5.5.2.4 Latin America
5.5.2.5 Rest of the world
5.6 PATENT ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA (HS CODE 382200)
5.7.2 EXPORT DATA (HS CODE 382200)
5.8 PRICING ANALYSIS
5.8.1 INDICATIVE AVERAGE SELLING PRICE TREND, BY REGION
5.9 KEY CONFERENCES AND EVENTS
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.10.2 BUYING CRITERIA
5.11 UNMET NEEDS/END-USER EXPECTATIONS IN LATERAL FLOW ASSAYS MARKET
5.12 VALUE CHAIN ANALYSIS
5.13 SUPPLY CHAIN ANALYSIS
5.14 IMPACT OF AI ON LATERAL FLOW ASSAYS MARKET
5.14.1 INTRODUCTION
5.14.2 MARKET POTENTIAL OF AI IN LATERAL FLOW ASSAYS MARKET
5.14.3 AI USE CASES
5.14.4 KEY COMPANIES IMPLEMENTING AI
5.14.5 FUTURE OF AI IN LATERAL FLOW ASSAYS MARKET
5.15 ECOSYSTEM ANALYSIS
5.16 CASE STUDY ANALYSIS
5.16.1 QUIDEL LAUNCHED NEW TEST WITH BROADER DETECTION WINDOW
5.16.2 ABINGTON OFFERED HIGH-SENSITIVITY TESTS FOR GREATER QUALITY
5.16.3 SIEMENS OFFERS HIGH-SENSITIVITY TROPONIN I ASSAY TO RAPIDLY DETECT ACUTE MYOCARDIAL INFARCTION
5.17 ADJACENT MARKETS FOR LATERAL FLOW ASSAYS MARKET
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.19 INVESTMENT AND FUNDING SCENARIO
5.20 IMPACT OF US TARIFF REGULATION ON LATERAL FLOW ASSAYS MARKET
5.20.1 INTRODUCTION
5.20.2 KEY TARIFF RATES
5.20.3 PRICE IMPACT ANALYSIS
5.20.4 KEY IMPACTS ON COUNTRY/REGION
5.20.4.1 North America
5.20.4.2 Europe
5.20.4.3 Asia Pacific
5.20.5 IMPACT ON END-USE INDUSTRIES
5.20.5.1 Hospitals and Clinics

6 LATERAL FLOW ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 KITS & REAGENTS
6.2.1 RISE IN DEMAND FOR POC TESTING TO DRIVE MARKET
6.3 READERS
6.3.1 DIGITAL/HANDHELD READERS
6.3.1.1 Technological evolution and demand for accuracy to drive adoption
6.3.2 BENCHTOP READERS
6.3.2.1 Lower diagnosis cost per patient to drive segment

7 LATERAL FLOW ASSAYS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 CLINICAL TESTING
7.2.1 INFECTIOUS DISEASE TESTING
7.2.1.1 Mosquito-borne diseases
7.2.1.1.1 Increase in incidence of dengue and introduction of more reliable test kits to drive market
7.2.1.2 Influenza
7.2.1.2.1 Rise in prevalence of influenza globally to boost market growth, despite lower sensitivity of lateral flow assays
7.2.1.3 Sexually transmitted infections
7.2.1.3.1 HIV
7.2.1.3.1.1 Growing need for early detection and awareness of HIV POC testing to drive market
7.2.1.3.2 HPV
7.2.1.3.2.1 Rapid HPV diagnostics and real-time PCR, covering broad range of genotypes, coupled with higher incidence of cervical cancer to drive segment
7.2.1.3.3 Chlamydia
7.2.1.3.3.1 Greater viability of advanced techniques to drive market
7.2.1.3.4 Gonorrhea
7.2.1.3.4.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
7.2.1.3.5 Syphilis
7.2.1.3.5.1 Need for early and accessible diagnosis to fuel growth
7.2.1.3.6 Other sexually transmitted infections
7.2.1.4 Hepatitis
7.2.1.4.1 Nucleic acid hybridization-based LFAs to show strong potential in hepatitis testing
7.2.1.5 Tuberculosis
7.2.1.5.1 Rise in prevalence and growing focus on early diagnosis and treatment to propel market
7.2.1.6 Other infectious diseases
7.2.2 CARDIAC MARKER TESTING
7.2.2.1 Troponin I & T
7.2.2.1.1 Introduction of high-sensitivity troponin assays to support market growth
7.2.2.2 CK-MB
7.2.2.2.1 Growing applications of lateral flow tests in acute myocardial injuries to drive market
7.2.2.3 BNP & NT-proBNP
7.2.2.3.1 Increase in demand for cardiac biomarker tests to detect heart stress and damage to support growth
7.2.2.4 Myoglobin
7.2.2.4.1 Availability of new high-sensitivity cardiac troponin assays to restrict market growth
7.2.2.5 D-Dimer
7.2.2.5.1 Rising incidence of CVDs to drive market for D-dimer tests
7.2.2.6 Other cardiac marker testing
7.2.3 PREGNANCY & FERTILITY TESTING
7.2.3.1 Pregnancy testing
7.2.3.1.1 Pregnancy testing to hold larger market share but register slower growth
7.2.3.2 Fertility testing
7.2.3.2.1 Rise in infertility rates to drive demand for POC fertility testing kits
7.2.4 CHOLESTEROL/LIPID TESTING
7.2.4.1 Lifestyle changes, cardiovascular disorder incidence to drive segment
7.2.5 DRUGS-OF-ABUSE TESTING
7.2.5.1 Technological advancements and rising focus on workplace drug testing to drive market
7.2.6 OTHER CLINICAL TESTS
7.3 VETERINARY DIAGNOSTICS
7.3.1 INFECTIOUS DISEASE OUTBREAKS AND TESTS AVAILABLE FOR DIFFERENT SPECIES TO DRIVE FRAGMENTED MARKET
7.4 FOOD SAFETY & ENVIRONMENT TESTING
7.4.1 HIGH SENSITIVITY AND EASE OF USE TO BOOST DEMAND FOR ASSAYS TO CLEAR FOODS FOR MARKET AVAILABILITY
7.5 DRUG DEVELOPMENT & QUALITY TESTING
7.5.1 GREATER FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO SUPPORT MARKET GROWTH

8 LATERAL FLOW ASSAYS MARKET, BY TECHNIQUE
8.1 INTRODUCTION
8.2 SANDWICH ASSAYS
8.2.1 WIDE RANGE OF APPLICATIONS IN CLINICAL TESTING TO SUPPORT MARKET GROWTH
8.3 COMPETITIVE ASSAYS
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY COMPARED TO SANDWICH ASSAYS TO HAMPER GROWTH
8.4 MULTIPLEX DETECTION ASSAYS
8.4.1 HIGHER ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO FUEL MARKET

9 LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE
9.1 INTRODUCTION
9.2 BLOOD SAMPLES
9.2.1 SIGNIFICANT USE OF BLOOD SAMPLES FOR INFECTIOUS DISEASE TESTING TO DRIVE MARKET
9.3 URINE SAMPLES
9.3.1 GROWING USE OF URINE SAMPLES FOR PREGNANCY AND DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
9.4 SALIVA SAMPLES
9.4.1 EASY AND LOW-COST COLLECTION, TRANSPORT, AND ANALYSIS OF SALIVA SAMPLES TO SUPPORT ADOPTION
9.5 OTHER SAMPLES

10 LATERAL FLOW ASSAYS MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS & CLINICS
10.2.1 HIGH DEMAND FOR DIAGNOSTICS ACROSS LARGE POOLS OF PATIENTS IN HOSPITALS TO DRIVE MARKET
10.3 HOME CARE SETTINGS
10.3.1 GROWING ACCEPTANCE OF REMOTE MONITORING TO PROPEL MARKET
10.4 DIAGNOSTIC LABORATORIES
10.4.1 LABORATORY TESTING LARGELY PREFERRED OVER PROFESSIONAL SETTINGS FOR URINE AND BLOOD TESTING
10.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.5.1 INCREASE IN FOCUS ON PRODUCT SAFETY TO DRIVE ADOPTION OF LATERAL FLOW ASSAYS
10.6 OTHER END USERS

11 LATERAL FLOW ASSAYS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Large patient base to drive market growth
11.2.3 CANADA
11.2.3.1 Availability of research funding and implementation of favorable government initiatives to drive market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Well-developed healthcare system and rise in geriatric population to fuel growth
11.3.3 UK
11.3.3.1 Growth in incidence of chronic conditions to propel market growth
11.3.4 FRANCE
11.3.4.1 High prevalence of age-related chronic diseases and infectious diseases to drive market
11.3.5 ITALY
11.3.5.1 Growth in initiatives toward decentralization of medical services to support market growth
11.3.6 SPAIN
11.3.6.1 Aging population and strong healthcare infrastructure to drive market
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Growing elderly population and well-developed healthcare system to drive market
11.4.3 CHINA
11.4.3.1 Modernized healthcare system to drive market
11.4.4 INDIA
11.4.4.1 Growth in healthcare concerns and rise in income levels to propel market growth, despite lack of reimbursement and insurance coverage for lateral flow assay products
11.4.5 AUSTRALIA
11.4.5.1 Rise in prevalence of infectious disease and healthcare expenditure to support growth
11.4.6 SOUTH KOREA
11.4.6.1 Growth in healthcare infrastructure to drive market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 High private healthcare expenditure and rise in geriatric population to drive market
11.5.3 MEXICO
11.5.3.1 Increase in demand for advanced medical equipment to drive market
11.5.4 ARGENTINA
11.5.4.1 Availability of health insurance to favor market growth
11.5.5 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.7 GCC COUNTRIES
11.7.1 RISE IN DEMAND FOR RAPID AND COST-EFFECTIVE DIAGNOSTICS TO DRIVE MARKET

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LATERAL FLOW ASSAYS MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Regional Footprint
12.7.5.3 Product Footprint
12.7.5.4 Technique Footprint
12.7.5.5 Application Footprint
12.7.5.6 Sample type Footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1 Detailed list of key startup/SME players
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 ABBOTT LABORATORIES
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches & approvals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 F. HOFFMANN-LA ROCHE LTD.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 MnM view
13.1.2.3.1 Right to win
13.1.2.3.2 Strategic choices
13.1.2.3.3 Weaknesses and competitive threats
13.1.3 DANAHER CORPORATION
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 MnM view
13.1.3.3.1 Right to win
13.1.3.3.2 Strategic choices
13.1.3.3.3 Weaknesses and competitive threats
13.1.4 QUIDELORTHOORTHO CORPORATION
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.5 SIEMENS AG
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.6 BECTON, DICKINSON AND COMPANY
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.7 BIOMERIEUX SA
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.8 THERMO FISHER SCIENTIFIC INC.
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.9 REVVITY, INC.
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.10 QIAGEN N.V.
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.11 MERCK KGAA
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Expansions
13.1.12 HOLOGIC, INC.
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.1.13 SURMODICS, INC.
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.14 ORASURE TECHNOLOGIES
13.1.14.1 Business overview
13.1.14.2 Products offered
13.2 OTHER PLAYERS
13.2.1 CHEMBIO DIAGNOSTICS INC.
13.2.2 DCN DIAGNOSTICS
13.2.3 POLYSCIENCES INC.
13.2.4 ABINGDON HEALTH
13.2.5 ORANOXIS INC.
13.2.6 AESKU.GROUP GMBH
13.2.7 BIO GROUP MEDICAL SYSTEM S.R.L
13.2.8 PHARMACT GMBH
13.2.9 XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
13.2.10 BIOPANDA REAGENTS LTD
13.2.11 ARTRON LABORATORIES INC.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS